MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573402 | Name: (R)-Azelastine hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(R)-Azelastine hydrochloride is an antihistamine which has been shown to down-regulate H1R, M1R and M3R levels. This compound has also been shown to inhibit HNEpC proliferation.

Chemical Structure

(R)-Azelastine hydrochloride
(R)-Azelastine hydrochloride
CAS#153408-28-7 (R-isomer HCl)

Theoretical Analysis

MedKoo Cat#: 573402

Name: (R)-Azelastine hydrochloride

CAS#: 153408-28-7 (R-isomer HCl)

Chemical Formula: C22H25Cl2N3O

Exact Mass: 417.1375

Molecular Weight: 418.36

Elemental Analysis: C, 63.16; H, 6.02; Cl, 16.95; N, 10.04; O, 3.82

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
79307-93-0 (HCl) 143228-85-7 (S-isomer) 143228-84-6 (R-isomer) 153408-27-6 (S-isomer HCl) 153408-28-7 (R-isomer HCl)
Synonym
(R)-Azelastine hydrochloride, Azelastine hydrochloride (R)-
IUPAC/Chemical Name
1(2H)-Phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride, (R)-
InChi Key
YEJAJYAHJQIWNU-GMUIIQOCSA-N
InChi Code
1S/C22H24ClN3O.ClH/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16;/h2-3,6-11,18H,4-5,12-15H2,1H3;1H/t18-;/m1./s1
SMILES Code
Cl.CN1CCC[C@H](CC1)N2N=C(Cc3ccc(Cl)cc3)c4ccccc4C2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 418.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Patterlini V, Guareschi F, D'Angelo D, Baldini S, Meto S, Mostafa Kamal D, Fabrizzi P, Buttini F, Mösges R, Sonvico F. Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays. Pharmaceutics. 2024 Jul 26;16(8):989. doi: 10.3390/pharmaceutics16080989. PMID: 39204334; PMCID: PMC11357686. 2: Tantilipikorn P, Kirtsreesakul V, Bunnag C, Vangveeravong M, Thanaviratananich S, Chusakul S. The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review. J Asthma Allergy. 2024 Jul 12;17:667-679. doi: 10.2147/JAA.S451733. PMID: 39045291; PMCID: PMC11264124. 3: Lin L, Zhu Y, Yuan K, Mou Y, Zhao H, Wu Y, Jin X. Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye. Adv Ophthalmol Pract Res. 2024 Feb 10;4(2):47-51. doi: 10.1016/j.aopr.2024.01.006. PMID: 38812946; PMCID: PMC11133755. 4: Reda A, Saleh H, Bahgat EA, Fawzy MG. Different Eco-Friendly Spectrophotometric Approaches Including Direct and Manipulations of Zero and Ratio Spectra for Simultaneous Determination of Novel Nasal Spray Combination Used in Seasonal Allergic Rhinitis. J AOAC Int. 2024 May 2;107(3):512-518. doi: 10.1093/jaoacint/qsae016. PMID: 38410058. 5: Shekhar S, Bali A. Method validation and characterization of stress degradation products of azelastine hydrochloride using LC-UV/PDA and LC-Q/TOF-MS studies. Rapid Commun Mass Spectrom. 2024 Apr 15;38(7):e9712. doi: 10.1002/rcm.9712. PMID: 38351666. 6: Marth K, Renner A, Langmayr G, Pohl W, Nguyen DT, Kuhl HC. An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu® in Austrian Patients with Persistent Allergic Rhinitis. Drugs Real World Outcomes. 2024 Jun;11(2):231-240. doi: 10.1007/s40801-023-00412-z. Epub 2024 Feb 13. PMID: 38351402; PMCID: PMC11176283. 7: Fischhuber K, Bánki Z, Kimpel J, Kragl N, Rössler A, Bolze A, Muellauer B, Angerer J, Nagy G, Nagy E, Szijarto V. Antiviral Potential of Azelastine against Major Respiratory Viruses. Viruses. 2023 Nov 23;15(12):2300. doi: 10.3390/v15122300. PMID: 38140540; PMCID: PMC10747764. 8: Zhou B, Cheng L, Pan J, Wang H, Jin Y, Zhao C, Lin P, Tan G, Fang H, Zhang H, Zhou H, Dong Y, Kuhl HC, Ramalingam RK, Nguyen DT. Correction: A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis. Pulm Ther. 2024 Mar;10(1):143-144. doi: 10.1007/s41030-023-00250-y. Erratum for: Pulm Ther. 2023 Sep;9(3):411-427. doi: 10.1007/s41030-023-00238-8. PMID: 38099987; PMCID: PMC10881919. 9: Trybus E, Trybus W, Król T. Cytological Study of Topical Effect of Azelastine Hydrochloride on the Nasal Mucous Membrane Cells in Various Nasal Rhinitis Types. Cells. 2023 Nov 24;12(23):2697. doi: 10.3390/cells12232697. PMID: 38067125; PMCID: PMC10706206. 10: Bousquet J, Klimek L, Kuhl HC, Nguyen DT, Ramalingam RK, Canonica GW, Berger WE. A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis. Front Allergy. 2023 Oct 18;4:1244012. doi: 10.3389/falgy.2023.1244012. PMID: 37920410; PMCID: PMC10619846. 11: Zhou B, Cheng L, Pan J, Wang H, Jin Y, Zhao C, Lin P, Tan G, Fang H, Zhang H, Zhou H, Dong Y, Kuhl HC, Ramalingam RK, Nguyen DT. A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis. Pulm Ther. 2023 Sep;9(3):411-427. doi: 10.1007/s41030-023-00238-8. Epub 2023 Aug 14. Erratum in: Pulm Ther. 2024 Mar;10(1):143-144. doi: 10.1007/s41030-023-00250-y. PMID: 37580498; PMCID: PMC10447793. 12: Kuratli J, Leonard CA, Schoborg R, Borel N. Anti-chlamydial effects of azelastine hydrochloride and the impact of the histamine H1 receptor on chlamydial development. J Med Microbiol. 2023 May;72(5). doi: 10.1099/jmm.0.001691. PMID: 37195751. 13: Musmade B, Korhale R, Sable M, Lokhande S, Padmanabhan S, Bhope S. Development and Validation of Stability-Indicating Impurity Profiling Method for Azelastine Hydrochloride and Fluticasone Propionate in Nasal Spray Product Using HPLC with a UV/PDA Detector. J AOAC Int. 2023 Jul 17;106(4):866-872. doi: 10.1093/jaoacint/qsad036. PMID: 36929921. 14: Fifer S, Toh L, Barkate H, Aggarwal V, Borade D, Gordonsmith RH, Wu W, Morgan C, Young K. Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study. Patient Prefer Adherence. 2023 Jan 15;17:141-151. doi: 10.2147/PPA.S389875. PMID: 36687019; PMCID: PMC9851056. 15: Stjärne P, Nguyen DT, Kuhl HC. Real-Life Effectiveness of MP-AzeFlu (Dymista®) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale. Pragmat Obs Res. 2023 Jan 4;14:1-11. doi: 10.2147/POR.S375403. PMID: 36628265; PMCID: PMC9826638. 16: Trybus E, Król T, Trybus W. The Multidirectional Effect of Azelastine Hydrochloride on Cervical Cancer Cells. Int J Mol Sci. 2022 May 24;23(11):5890. doi: 10.3390/ijms23115890. PMID: 35682572; PMCID: PMC9180047. 17: Zheng Q, Ma D, Zhu Q, Tang S, Chen C. Effect of azelastine hydrochloride combined with montelukast sodium in the treatment of patients with allergic rhinitis. Am J Transl Res. 2021 Aug 15;13(8):9570-9577. PMID: 34540080; PMCID: PMC8430178. 18: El-Masry AA, El-Wasseef DR, Eid M, Shehata IA, Zeid AM. Quantitative proton nuclear magnetic resonance method for simultaneous analysis of fluticasone propionate and azelastine hydrochloride in nasal spray formulation. R Soc Open Sci. 2021 Jul 14;8(7):210483. doi: 10.1098/rsos.210483. PMID: 34277026; PMCID: PMC8278066. 19: Shikh EV, Eremenko NN, Arefev KI. Farmakoterapiya allergicheskogo rinita: pozitsiya klinicheskogo farmakologa [Pharmacotherapy of allergic rhinitis: position of a clinical pharmacologist]. Vestn Otorinolaringol. 2021;86(3):118-126. Russian. doi: 10.17116/otorino202186031118. PMID: 34269035. 20: Woo IS, Kim JH, Kim YK, Kim HI, Shin DW, Kim JH, Baek SY. Development and validation of a simultaneous analytical method for non-steroidal therapeutic compounds in cosmetics using liquid chromatography-tandem mass spectrometry. J Sep Sci. 2021 Jun;44(12):2371-2381. doi: 10.1002/jssc.202001267. Epub 2021 Apr 28. PMID: 33837635.